Skip to main content
. 2007 Feb 28;81(10):5225–5237. doi: 10.1128/JVI.02564-06

TABLE 2.

IFN-γ ELISPOT responses to epitope variants with PBMC from HIV-1 infected subjects

PTE peptidea HXB2 aa position Epitope sequenceb BLOSUM score(s)c Subject/epitope/HLA restrictiond
1212/AL9/B62
1238/AL9/Cw08
1188/WF9/B1503
SFC/106 PBMC 15-mer SFC/106 PBMC 9-mer EC50 ng/ml 9-mer SFC/106 PBMC 15-mer SFC/106 PBMC 9-mer EC50 ng/ml 9-mer SFC/106 15-mer SFC/106 9-mer EC50 ng/ml 9-mer
Epitope AL9
    YKAAVDLSHFLKEKG 081-095 AAVDLSHFL 191 270 0.42 287 726 7.99
    PMTYKAAVDLSHFLK 078-092 ......... 222 270 0.42 690 726 7.99
    RPMTYKGAVDLSHFL 077-091 G........ 0 402 245 3.87 700 542 19.40
    RPMTYKAALDLSHFL 077-091 ..L...... 1 276 200 0.55 Not reactive 179 202.00
    TRRAAIDLSHFLREK 080-094 ..I...... 3 Not reactive 260 6.46 95 726 20.30
    PMTFKGALDLSHFLR 078-092 G.L...... 0, 1 Not reactive 205 39.23 Not reactive 136 909.00
    GALDLSHFLKEKGGL 083-097 G.L...... 0, 1 Not reactive 205 39.23 Not reactive 136 909.00
    PMTYKGAFDLSHFLK 078-092 G.F...... 0, −1 61 120 70.80 Not reactive Not reactive
Epitope WF9
    EREVLEWKFDSRLAF 177-191 WKFDSRLAF 2,826 1,335 69.60
    VLVWKFDSRLAFRHM 180-194 ......... 1,436 1,335 69.60
    VLMWKFDSRLAFHHI 180-194 ......... 1,013 1,335 69.60
    WRFDSRLAFHHMARE 183-197 .R....... 2 949 950 563.43
    EVLQWKFDSRLALRH 179-193 ........L 0 753 1,343 37.55
    LVWKFDSSLAFHHRA 181-195 .....S... −1 350 148 17.23
    LVWKFDSHLAFHHMA 181-195 .....H... 0 123 290 16.44
    VWRFDSHLAFRHMAR 182-196 .R...H... 2, 0 106 270 17.16
a

Amino acid differences from the CON sequence are underscored. The optimal epitope sequence is in bold type.

b

The CON B sequence for each epitope is indicated on the top. Identity to the amino acid in the CON sequence is indicated by a dot. All epitopes shown were previously mapped and HLA restriction was performed (9).

c

Conservative amino acid substitutions are denoted by positive scores and nonconservative substitutions by negative scores. The scoring is on a scale of −4 to +3.

d

All SFC data shown were obtained from IFN-γ ELISPOT assays performed at 2 μg/ml. Response levels of >50 SFC/106 PBMC were designated reactive. EC50, effective peptide concentration that elicited 50% of the maximum T-cell response.